LRMR
Larimar Therapeutics Inc
3.00$
-3.3%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
Larimar Therapeutics Inc (LRMR) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -44 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 15 | Q4 15 | Q1 16 | Q4 16 | Q1 17 | Q4 17 | Q1 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -11 | -48 | -18 | 18 | -12 | 12 | -13 | -13 | -38 | -5.8 | -3.2 | -5.8 | -7.9 | -8.9 | -12 | -11 | -9.9 | -11 | -11 | -12 | -7.9 | -7.5 | -7.5 | -5.9 | -6.7 | -7.6 | -7.4 | -9.2 | -9.3 | -10 | -14 | -25 | -22 | -27 | -19 | -29 | -39 | -45 | -44 | -156 | |
| 0.1 | 1.2 | 0.5 | -0.5 | 0.1 | -0.1 | 0.0 | 0.1 | -0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.3 | |
| 1.1 | 7.5 | 2.8 | -2.8 | 2.0 | -2.0 | 2.5 | – | 7.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.8 | 0.4 | 1.0 | 1.2 | 1.4 | 1.5 | 1.5 | 1.6 | 1.7 | 1.7 | 1.6 | 1.8 | 2.0 | 1.8 | 1.9 | 2.1 | 2.3 | 2.0 | 2.4 | 1.8 | 1.8 | 1.8 | 1.6 | 2.0 | 2.1 | 7.5 | |
| – | – | – | – | – | – | – | – | – | 0.0 | 0.0 | 0.0 | – | 0.0 | 0.8 | 0.4 | 1.0 | 1.2 | 1.3 | 1.5 | 1.5 | 1.6 | 1.7 | 1.6 | 0.9 | 1.8 | 2.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 1.1 | -1.1 | -4.1 | 4.1 | -0.7 | 0.7 | 0.8 | 0.0 | -0.8 | -1.2 | -0.1 | 2.8 | -1.9 | -2.3 | -1.7 | -1.4 | 3.3 | -0.4 | 0.4 | 3.1 | -0.4 | -0.3 | -0.6 | 0.8 | 1.8 | -2.3 | -1.1 | -1.5 | 2.3 | 2.7 | 7.1 | -9.3 | 5.8 | 1.6 | 5.4 | 17 | 23 | -17 | -12 | 11 | |
| 0.0 | 0.6 | 0.4 | 0.4 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | 0.0 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.0 | 0.3 | 0.1 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.2 | |
| -70 | -22 | 14 | -14 | 8.7 | -8.7 | 18 | -47 | -25 | 0.0 | 0.0 | -0.8 | -0.1 | -0.8 | 41 | 0.0 | -24 | 5.3 | 19 | -6.8 | 6.5 | -35 | -35 | -3.4 | -52 | 92 | -9.8 | -46 | -2.6 | -68 | -63 | 27 | 19 | 14 | 19 | 33 | 34 | 29 | -41 | 55 | |
| – | – | – | – | – | – | – | – | – | 0.1 | 0.1 | 0.0 | -0.1 | 0.0 | 75 | 0.0 | -75 | -75 | – | 20 | – | – | – | – | 0.0 | – | – | – | – | – | -0.3 | 0.3 | – | – | – | – | – | – | – | – | |
| 130 | -0.5 | -0.7 | 0.7 | -0.7 | 0.7 | 0.3 | 65 | 67 | 3.0 | 3.0 | 10.0 | 3.5 | 9.6 | 84 | -0.1 | 0.2 | 0.2 | 20 | 20 | 76 | 76 | 76 | 76 | -0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 162 | -0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 65 | -0.2 | 108 | -0.4 | 173 | |
| 49 | -71 | -4.1 | 4.1 | -3.7 | 3.7 | 5.0 | – | 3.6 | -48 | -0.2 | 4.1 | -42 | -0.1 | 113 | -11 | -33 | -6.0 | 8.4 | 0.9 | -1.4 | -7.5 | -43 | 66 | -59 | 85 | -17 | -56 | -12 | 83 | -78 | 2.8 | -2.6 | -12 | -0.5 | 70 | -4.7 | 93 | -85 | 72 | |
| -11 | -49 | -18 | 18 | -12 | 12 | -13 | -13 | -38 | -5.8 | -3.2 | -5.8 | -8.0 | -9.0 | -12 | -11 | -9.9 | -11 | -11 | -12 | -7.9 | -7.5 | -7.6 | -5.9 | -6.7 | -7.6 | -7.4 | -9.2 | -9.5 | -10 | -14 | -25 | -22 | -27 | -19 | -29 | -39 | -45 | -44 | -156 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.